Literature DB >> 19749203

Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I).

Charles S Berenson1, Hesham F Nawar, Herbert C Yohe, Sherry A Castle, David J Ashline, Vernon N Reinhold, George Hajishengallis, Terry D Connell.   

Abstract

LT-IIb, a type II heat-labile enterotoxin of Escherichia coli, is a potent immunologic adjuvant with high affinity binding for ganglioside GD1a. Earlier study suggested that LT-IIb bound preferentially to the terminal sugar sequence NeuAcalpha2-3Galbeta1-3GalNAc. However, studies in our laboratory suggested a less restrictive binding epitope. LT-IIb(T13I), an LT-IIb variant, engineered by a single isoleucine-threonine substitution, retains biological activity, but with less robust inflammatory effects. We theorized that LT-IIb has a less restrictive binding epitope than previously proposed and that immunologic differences between LT-IIb and LT-IIb (T13I) correlate with subtle ganglioside binding differences. Ganglioside binding epitopes, determined by affinity overlay immunoblotting and enzymatic degradation of ganglioside components of RAW264.7 macrophages, indicated that LT-IIb bound to a broader array of gangliosides than previously recognized. Each possessed NeuAcalpha2-3Galbeta1-3GalNAc, although not necessarily as a terminal sequence. Rather, each had a requisite terminal or penultimate single sialic acid and binding was independent of ceramide composition. RAW264.7 enterotoxin-binding and non-binding ganglioside epitopes were definitively identified as GD1a and GM1a, respectively, by enzymatic degradation and mass spectroscopy. Affinity overlay immunoblots, constructed to the diverse array of known ganglioside structures of murine peritoneal macrophages, established that LT-IIb bound NeuAc- and NeuGc-gangliosides with nearly equal affinity. However, LT-IIb(T13I) exhibited enhanced affinity for NeuGc-gangliosides and more restrictive binding. These studies further elucidate the binding epitope for LT-IIb and suggest that the diminished inflammatory activity of LT-IIb(T13I) is mediated by a subtle shift in ganglioside binding. These studies underscore the high degree of specificity required for ganglioside-protein interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19749203      PMCID: PMC2782182          DOI: 10.1093/glycob/cwp141

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  40 in total

1.  Specificity in protein-membrane associations: the interaction of gangliosides with Escherichia coli heat-labile enterotoxin and choleragen.

Authors:  J C Osborne; J Moss; P H Fishman; S Nakaya; D C Robertson
Journal:  Biophys J       Date:  1982-01       Impact factor: 4.033

2.  Mechanism of activation of adenylate cyclase by Vibrio cholerae enterotoxin.

Authors:  V Bennett; P Cuatrecasas
Journal:  J Membr Biol       Date:  1975-06-03       Impact factor: 1.843

3.  Ganglioside and rabbit erythrocyte membrane receptor for staphylococcal alpha-toxin.

Authors:  I Kato; M Naiki
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

4.  A unique glycosphingolipid-splitting enzyme (ceramide-glycanase from leech) cleaves the linkage between the oligosaccharide and the ceramide.

Authors:  S C Li; R DeGasperi; J E Muldrey; Y T Li
Journal:  Biochem Biophys Res Commun       Date:  1986-11-26       Impact factor: 3.575

5.  Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin.

Authors:  Emma Byres; Adrienne W Paton; James C Paton; Jonas C Löfling; David F Smith; Matthew C J Wilce; Ursula M Talbot; Damien C Chong; Hai Yu; Shengshu Huang; Xi Chen; Nissi M Varki; Ajit Varki; Jamie Rossjohn; Travis Beddoe
Journal:  Nature       Date:  2008-10-29       Impact factor: 49.962

6.  Elimination of oxidative degradation during the per-O-methylation of carbohydrates.

Authors:  Ionel Ciucanu; Catherine E Costello
Journal:  J Am Chem Soc       Date:  2003-12-31       Impact factor: 15.419

7.  N-glycolyl GM1 ganglioside as a receptor for simian virus 40.

Authors:  Maria A Campanero-Rhodes; Alicia Smith; Wengang Chai; Sandro Sonnino; Laura Mauri; Robert A Childs; Yibing Zhang; Helge Ewers; Ari Helenius; Anne Imberty; Ten Feizi
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

8.  Mutational analysis of the ganglioside-binding activity of the type II Escherichia coli heat-labile enterotoxin LT-IIb.

Authors:  T D Connell; R K Holmes
Journal:  Mol Microbiol       Date:  1995-04       Impact factor: 3.501

9.  Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb.

Authors:  S Fukuta; J L Magnani; E M Twiddy; R K Holmes; V Ginsburg
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

Review 10.  Diversity in cell surface sialic acid presentations: implications for biology and disease.

Authors:  Nissi M Varki; Ajit Varki
Journal:  Lab Invest       Date:  2007-07-16       Impact factor: 5.662

View more
  15 in total

1.  Membrane interaction of Pasteurella multocida toxin involves sphingomyelin.

Authors:  Michael C Brothers; Mengfei Ho; Ram Maharjan; Nathan C Clemons; Yuka Bannai; Mark A Waites; Melinda J Faulkner; Theresa B Kuhlenschmidt; Mark S Kuhlenschmidt; Steven R Blanke; Chad M Rienstra; Brenda A Wilson
Journal:  FEBS J       Date:  2011-10-20       Impact factor: 5.542

2.  Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments.

Authors:  Gautam N Shenoy; Jenni Loyall; Charles S Berenson; Raymond J Kelleher; Vandana Iyer; Sathy V Balu-Iyer; Kunle Odunsi; Richard B Bankert
Journal:  J Immunol       Date:  2018-11-16       Impact factor: 5.422

3.  Investigation of substrate specificity of sialidases with membrane mimetic glycoconjugates.

Authors:  Sonia Tomar; Xue-Long Sun
Journal:  Glycoconj J       Date:  2019-12-04       Impact factor: 2.916

4.  TLR2-dependent modulation of dendritic cells by LT-IIa-B5, a novel mucosal adjuvant derived from a type II heat-labile enterotoxin.

Authors:  Chang Hoon Lee; Patricia Masso-Welch; George Hajishengallis; Terry D Connell
Journal:  J Leukoc Biol       Date:  2011-07-26       Impact factor: 4.962

Review 5.  Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.

Authors:  George Hajishengallis; Terry D Connell
Journal:  Vet Immunol Immunopathol       Date:  2012-09-26       Impact factor: 2.046

6.  LT-IIc, a new member of the type II heat-labile enterotoxin family, exhibits potent immunomodulatory properties that are different from those induced by LT-IIa or LT-IIb.

Authors:  Hesham F Nawar; Christopher J Greene; Chang Hoon Lee; Lorrie M Mandell; George Hajishengallis; Terry D Connell
Journal:  Vaccine       Date:  2010-11-21       Impact factor: 3.641

7.  Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration.

Authors:  Camila Mathias-Santos; Juliana F Rodrigues; Maria Elisabete Sbrogio-Almeida; Terry D Connell; Luís C S Ferreira
Journal:  Clin Vaccine Immunol       Date:  2011-06-15

8.  Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I).

Authors:  Hesham F Nawar; Charles S Berenson; George Hajishengallis; Hiromu Takematsu; Lorrie Mandell; Ragina L Clare; Terry D Connell
Journal:  Clin Vaccine Immunol       Date:  2010-04-14

9.  Ganglioside-binding specificities of E. coli enterotoxin LT-IIc: Importance of long-chain fatty acyl ceramide.

Authors:  Charles S Berenson; Hesham F Nawar; Ragina L Kruzel; Lorrie M Mandell; Terry D Connell
Journal:  Glycobiology       Date:  2012-08-22       Impact factor: 4.313

10.  LT-IIc, a new member of the type II heat-labile enterotoxin family encoded by an Escherichia coli strain obtained from a nonmammalian host.

Authors:  Hesham F Nawar; Natalie D King-Lyons; John C Hu; Raymond C Pasek; Terry D Connell
Journal:  Infect Immun       Date:  2010-08-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.